102 related articles for article (PubMed ID: 10592765)
1. Evaluation of the prognostic value of serum soluble CD 44 in patients with breast cancer.
Sheen-Chen SM; Chen WJ; Eng HL; Sheen CC; Chou FF; Cheng YF
Cancer Invest; 1999; 17(8):581-5. PubMed ID: 10592765
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of hepatocyte growth factor in patients with breast cancer.
Sheen-Chen SM; Liu YW; Eng HL; Chou FF
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):715-7. PubMed ID: 15767355
[TBL] [Abstract][Full Text] [Related]
3. Serum-soluble interleukin-2 receptor concentrations in patients with breast cancer: a preliminary report.
Sheen-Chen SM; Chen WJ; Eng HL; Chou FF
Changgeng Yi Xue Za Zhi; 1998 Jun; 21(2):133-8. PubMed ID: 9729645
[TBL] [Abstract][Full Text] [Related]
4. Soluble CD44 v5 and v6 in serum of patients with breast cancer. Correlation with expression of CD44 v5 and v6 variants in primary tumors and location of distant metastasis.
Lackner C; Moser R; Bauernhofer T; Wilders-Truschnig M; Samonigg H; Berghold A; Zatloukal K
Breast Cancer Res Treat; 1998 Jan; 47(1):29-40. PubMed ID: 9493973
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of circulating intercellular adhesion molecule-1 in patients with breast cancer.
Sheen-Chen SM; Eng HL; Sheen CW; Cheng YF; Chou FF; Chen WJ
Anticancer Res; 1997; 17(4A):2823-6. PubMed ID: 9252723
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of adhesion molecule CD44v6 in women with primary breast carcinoma: a clinicopathologic study.
Ma W; Deng Y; Zhou L
Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):258-63. PubMed ID: 15997921
[TBL] [Abstract][Full Text] [Related]
8. Serum concentration of tumor necrosis factor in patients with breast cancer.
Sheen-Chen SM; Chen WJ; Eng HL; Chou FF
Breast Cancer Res Treat; 1997 May; 43(3):211-5. PubMed ID: 9150900
[TBL] [Abstract][Full Text] [Related]
9. Circulating soluble Fas in patients with breast cancer.
Sheen-Chen SM; Chen HS; Eng HL; Chen WJ
World J Surg; 2003 Jan; 27(1):10-3. PubMed ID: 12557031
[TBL] [Abstract][Full Text] [Related]
10. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M
Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810
[TBL] [Abstract][Full Text] [Related]
11. Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients.
Pinto AE; André S; Soares J
J Clin Pathol; 1999 Aug; 52(8):604-11. PubMed ID: 10645231
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of CD44 and CD44v6 in colorectal carcinoma patients: soluble forms in relation to tumor tissue expression and metastasis.
Amirghofran Z; Jalali SA; Hosseini SV; Vasei M; Sabayan B; Ghaderi A
J Gastrointest Cancer; 2008; 39(1-4):73-8. PubMed ID: 19333790
[TBL] [Abstract][Full Text] [Related]
13. Serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant v5 (sCD44-v5), and CD44 splice variant v6 (sCD44-v6) in patients with epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Fanucchi A; Annicchiarico C; Cosio S; Prontera C; Bianchi R; Genazzani AR
Anticancer Res; 1997; 17(6D):4463-6. PubMed ID: 9494551
[TBL] [Abstract][Full Text] [Related]
14. Soluble CD44 isoforms in serum as potential markers of metastatic gastric carcinoma.
Harn HJ; Ho LI; Shyu RY; Yuan JS; Lin FG; Young TH; Liu CA; Tang HS; Lee WH
J Clin Gastroenterol; 1996 Mar; 22(2):107-10. PubMed ID: 8742647
[TBL] [Abstract][Full Text] [Related]
15. Soluble CD44 splice variants in metastasizing human breast cancer.
Martin S; Jansen F; Bokelmann J; Kolb H
Int J Cancer; 1997 Aug; 74(4):443-5. PubMed ID: 9291436
[TBL] [Abstract][Full Text] [Related]
16. The expression of variant exon v7-v8 CD44 antigen in relation to lymphatic metastasis of human breast cancer.
Kinoshita J; Haga S; Shimizu T; Imamura H; Watanabe O; Kajiwara T
Breast Cancer Res Treat; 1999 Jan; 53(2):177-83. PubMed ID: 10326795
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of transforming growth factor beta1 in patients with breast cancer.
Sheen-Chen SM; Chen HS; Sheen CW; Eng HL; Chen WJ
Arch Surg; 2001 Aug; 136(8):937-40. PubMed ID: 11485532
[TBL] [Abstract][Full Text] [Related]
18. CD44 variant exon epitopes in primary breast cancer and length of survival.
Kaufmann M; Heider KH; Sinn HP; von Minckwitz G; Ponta H; Herrlich P
Lancet; 1995 Mar; 345(8950):615-9. PubMed ID: 7534855
[TBL] [Abstract][Full Text] [Related]
19. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer.
Isola J; Weitz S; Visakorpi T; Holli K; Shea R; Khabbaz N; Kallioniemi OP
J Clin Oncol; 1993 Jan; 11(1):36-43. PubMed ID: 8093367
[TBL] [Abstract][Full Text] [Related]
20. A CD44 variant exon 6 epitope as a prognostic indicator in breast cancer.
Schumacher U; Horny HP; Horst HA; Herrlich P; Kaiserling E
Eur J Surg Oncol; 1996 Jun; 22(3):259-61. PubMed ID: 8654608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
